|
1
|
Forbes JF, Sestak I, Howell A, Bonanni B,
Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M,
et al: IBIS-II investigators: Anastrozole versus tamoxifen for the
prevention of locoregional and contralateral breast cancer in
postmenopausal women with locally excised ductal carcinoma in situ
(IBIS-II DCIS): A double-blind, randomised controlled trial.
Lancet. 387:866–873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pu Z, Zhang X, Chen Q, Yuan X and Xie H:
Establishment of an expression platform of OATP1B1 388GG and 521CC
genetic polymorphism and the therapeutic effect of tamoxifen in
MCF-7 cells. Oncol Rep. 33:2420–2428. 2015.PubMed/NCBI
|
|
3
|
Aihara T, Yokota I, Hozumi Y, Aogi K,
Iwata H, Tamura M, Fukuuchi A, Makino H, Kim R, Andoh M, et al:
Anastrozole versus tamoxifen as adjuvant therapy for Japanese
postmenopausal patients with hormone-responsive breast cancer:
Efficacy results of long-term follow-up data from the N-SAS BC
03 trial. Breast Cancer Res Treat. 148:337–343. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang J, Xu B, Yuan P, Ma F and Li Q, Zhang
P, Cai R, Fan Y, Luo Y and Li Q: Capecitabine combined with
docetaxel versus vinorelbine followed by capecitabine maintenance
medication for first-line treatment of patients with advanced
breast cancer: phase 3 randomized trial. Cancer. 121:3412–3421.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Witt CM, Außerer O, Baier S, Heidegger H,
Icke K, Mayr O, Mitterer M, Roll S, Spizzo G, Scherer A, et al:
Effectiveness of an additional individualized multi-component
complementary medicine treatment on health-related quality of life
in breast cancer patients: A pragmatic randomized trial. Breast
Cancer Res Treat. 149:449–460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu YC, Zhang FC, Li JJ, Dai JQ, Liu Q,
Tang L, Ma Y, Xu Q, Lin XL, Fan HB, et al: RRM1, TUBB3, TOP2A,
CYP19A1, CYP2D6: Difference between mRNA and protein expression in
predicting prognosis of breast cancer patients. Oncol Rep.
34:1883–1894. 2015.PubMed/NCBI
|
|
7
|
Leng XF, Chen MW, Xian L, Dai L, Ma GY and
Li MH: Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1,
RRM1 and TUBB3 to predict prognosis in patients with non-small cell
lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer
Res. 31:252012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang ZL, Cao X, Luo RZ, Chen YF, Zhu LC
and Wen Z: Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors
of prognosis in patients with non-small cell lung cancer who
received cisplatin-based adjuvant chemotherapy: A prospective
study. Oncol Lett. 11:299–305. 2016.PubMed/NCBI
|
|
9
|
Narvi E, Jaakkola K, Winsel S,
Oetken-Lindholm C, Halonen P, Kallio L and Kallio MJ: Altered TUBB3
expression contributes to the epothilone response of mitotic cells.
Br J Cancer. 108:82–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huijsmans CJ, van den Brule AJ, Rigter H,
Poodt J, van der Linden JC, Savelkoul PH, Hilbink M and Hermans MH:
Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn
Pathol. 10:562015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fasching PA, Weihbrecht S, Haeberle L,
Gasparyan A, Villalobos IE, Ma Y, Ekici AB, Wachter DL, Hartmann A,
Beckmann MW, et al: HER2 and TOP2A amplification in a
hospital-based cohort of breast cancer patients: Associations with
patient and tumor characteristics. Breast Cancer Res Treat.
145:193–203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fountzilas G, Valavanis C, Kotoula V,
Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R,
Wirtz RM, Bobos M, et al: HER2 and TOP2A in high-risk early breast
cancer patients treated with adjuvant epirubicin-based dose-dense
sequential chemotherapy. J Transl Med. 10:102012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li SZ, Qiao SF, Zhang JH and Li K:
Quercetin increase the chemosensitivity of breast cancer cells to
doxorubicin via PTEN/Akt pathway. Anticancer Agents Med Chem.
15:1185–1189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su R, Nan H, Guo H, Ruan Z, Jiang L, Song
Y and Nan K: Associations of components of PTEN/AKT/mTOR pathway
with cancer stem cell markers and prognostic value of these
biomarkers in hepatocellular carcinoma. Hepatol Res. Mar
2–2016.(Epub ahead of print). doi: 10.1111/hepr.12687. View Article : Google Scholar
|
|
15
|
Zheng S, Song QK, Zhao L, Huang R, Sun L,
Li J, Fan JH, Zhang BN, Yang HJ, Xu F, et al: Characteristics of
mammary Paget's disease in China: A national-wide multicenter
retrospective study during 1999–2008. Asian Pac J Cancer Prev.
13:1887–1893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seidman AD, Chan S, Wang J, Zhu C, Xu C
and Xu B: A pooled analysis of gemcitabine plus docetaxel versus
capecitabine plus docetaxel in metastatic breast cancer.
Oncologist. 19:443–452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun S, Shi W, Wu Z, Zhang G, Yang BO and
Jiao S: Prognostic significance of the mRNA expression of ERCC1,
RRM1, TUBB3 and TYMS genes in patients with non-small cell lung
cancer. Exp Ther Med. 10:937–941. 2015.PubMed/NCBI
|
|
18
|
Zou ZQ, Du YY, Sui G and Xu SN: Expression
of TS, RRM1, ERCC1, TUBB3 and STMN1 genes in tissues of non-small
cell lung cancer and its significance in guiding postoperative
adjuvant chemotherapy. Asian Pac J Cancer Prev. 16:3189–3194. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakagawa M, Bando Y, Nagao T, Takai C,
Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Tangoku A, et
al: Among triple-negative breast cancers, HER2(0) breast cancer
shows a strong tendency to be basal-like compared with HER2(1+)
breast cancer: preliminary results. Breast Cancer. 19:54–59. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang F, Lyu S, Dong S, Liu Y, Zhang X and
Wang O: Expression profile analysis of long noncoding RNA in
HER-2-enriched subtype breast cancer by next-generation sequencing
and bioinformatics. Onco Targets Ther. 9:761–772. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shih MC, Chen JY, Wu YC, Jan YH, Yang BM,
Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, et al: TOPK/PBK
promotes cell migration via modulation of the PI3K/PTEN/AKT pathway
and is associated with poor prognosis in lung cancer. Oncogene.
31:2389–2400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qadir XV, Han C, Lu D, Zhang J and Wu T:
miR-185 inhibits hepatocellular carcinoma growth by targeting the
DNMT1/PTEN/Akt pathway. Am J Pathol. 184:2355–2364. 2014.
View Article : Google Scholar : PubMed/NCBI
|
